65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample — 35.6; 30.3; 29.1; 25.0 Percentage of Patients
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL · Leukemia Cutis · Recurrent Acute Myeloid Leukemia
Primary: Incidence of Dose-limiting Toxicities (DLTs) (Phase Ib)
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Insomnia · Sleep-Disordered Breathing
Primary: Insomnia Severity Index — 9.29; 13.21 units on a scale
Solid Tumor · Non-Small Cell Lung Cancer Recurrent · Hepatocellular Carcinoma Recurrent
Primary: Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab — 300 milligrams (mg)
Schizophrenia Relapse
Primary: Number of Participants With Relapse — 130 Participants
Dizziness
Primary: Vestibular Reaction Times — 240.89; 202.96; 233.09; 228.95 msec
Myeloma-Multiple · Myeloma, Plasma-Cell
Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…
Radiation Dermatitis
Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale
Primary Malignant Liver Neoplasm
Primary: Image Quality for 90-Y PET/CT Scans — 3.56; 4.63; 4.89; 4.93 units on a scale
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities
Cancer · Pain
Primary: Bioavailability of Ketamine — 0; 0; 0; 13.4 ng/mL
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Reduction in Hypertrophic Skin Scarring
Primary: Physician Observer Scar Assessment Score at Week 24 — 0.0; -0.5; 0.8; -0.3 units on a scale — p=1.000
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 38; 31; 30; 98 Participants